🔬
India bears the highest global burden of head and neck cancers. Our program combines de-intensification strategies with novel immunotherapy approaches.
Learn MoreGenomic and epigenomic characterization of tobacco-driven head and neck cancers prevalent in the Indian population.
Reducing treatment toxicity in favourable-prognosis patients through response-adapted radiation dose reduction.
Evaluating novel checkpoint inhibitor combinations and tumour-infiltrating lymphocyte therapy for platinum-refractory cancers.
Prospective studies on functional outcomes and quality of life after organ-preserving treatments.
NCT06234510
RecruitingPI: Dr. Arvind Krishnamurthy
NCT06234511
ActivePI: Dr. Selvaluxmy Ganapathy
Your contribution funds research into less toxic treatments that preserve speech, swallowing, and quality of life for patients with head and neck cancers.
Donate Now
.png&w=96&q=75){kind=small}